Thérapies de Conversion

Oncological Outcomes Following Different TACE-Based Conversion Therapies for Intermediate-Advanced Hepatocellular Carcinoma.

Xu H, Liu Y, Zhang H, Wu H, Li B, Chen K, Wei Y

Cancer Med . 2026;15 (4) :e71867

📅 01/04/2026 PMID : 42010776 DOI : 10.1002/cam4.71867

Résumé

BACKGROUND: Transcatheter arterial chemoembolization (TACE) is widely used for intermediate-advanced hepatocellular carcinoma (HCC). The efficacy and safety of TACE combined with systemic treatments as conversion therapy for HCC remain to be explored.METHODS: Patients with intermediate-advanced HCC were divided as following groups based on therapy: (1) TACE; (2) TACE combined with tyrosine kinase inhibitors (TACE+TKI); (3) TACE+TKI and immune checkpoint inhibitors (TACE+TKI+ICI); and (4) TACE combined with Bevacizumab and ICI. The progression-free survival (PFS), overall survival (OS), treatment responses, and adverse events (AEs) were evaluated.RESULTS: Of the enrolled 518 patients, the overall objective response rate (ORR) was 21.0% and disease control rate (DCR) was 63.7%, while the TACE+TKI+ICI group showed highest ORR (28.9%) and DCR (72.8%). 147 (28.4%) patients experienced AEs during treatments. The TACE+TKI+ICI group significantly improved survival compared to TACE (mPFS: 20.7 vs. 10.9 months, p